In summary, we report that miR-575-CDKN1B feedback loop is involved in tamoxifen sensitivity in ER+ breast cancer (Figure 8H) and that miR-575 can be used as a prognostic biomarker in these patients as well as a predictor or a promising target for tamoxifen resistance. Here, ESR1 is linked to breast carcinoma.